Form 4: Mira Pharmaceuticals Director Acquires 50,000 Stock Options

Director Denil Nanji Shekhat of Mira Pharmaceuticals acquired 50,000 stock options with an exercise price of $1.19 on December 9, 2024.

Summary

• Denil Nanji Shekhat, a director at Mira Pharmaceuticals, acquired 50,000 stock options on December 9, 2024.
• The exercise price for these options is $1.19 per share, which was the closing price of the company's common stock on December 6, 2024.
• These options were granted under the company's 2022 Omnibus Incentive Plan.
• The options vest in two equal tranches: 50% will vest six months after the grant date, and the remaining 50% will vest one year after the grant date.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of stock options to a director, which is generally positive for aligning interests, but not a major event.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

This is a standard practice for incentivizing directors and aligning their interests with the company's performance and shareholder value.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors in publicly traded companies, particularly in the pharmaceutical and biotech sectors.
• The vesting schedule of six months and one year is fairly standard, designed to encourage long-term commitment and performance.
• The exercise price being set at the closing price on the grant date is also a typical practice.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially leading to increased focus on long-term value creation.

Key Dates

Keywords

stock options, insider trading, beneficial ownership, MIRA Pharmaceuticals, director, equity compensation